{"id":56281,"date":"2026-02-04T22:32:09","date_gmt":"2026-02-04T14:32:09","guid":{"rendered":"https:\/\/flcube.com\/?p=56281"},"modified":"2026-02-04T22:32:10","modified_gmt":"2026-02-04T14:32:10","slug":"wuhan-yzy-biopharma-gets-fda-nod-for-m701-phase-ib-ii-mpe-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56281","title":{"rendered":"Wuhan YZY Biopharma Gets FDA Nod for M701 Phase Ib\/II MPE Study"},"content":{"rendered":"\n

Wuhan YZY Biopharma Co., Ltd<\/strong> (HKG: 2496<\/a>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has approved an open\u2011label, multicenter Phase Ib\/II clinical study<\/strong> for its independently developed bispecific antibody drug M701<\/strong> in malignant pleural effusion (MPE)<\/strong>. The study will assess safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity.<\/p>\n\n\n\n

Regulatory Milestone & Drug Profile<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Wuhan YZY Biopharma Co., Ltd (2496.HK)<\/td><\/tr>
Drug<\/strong><\/td>M701 (bispecific antibody)<\/td><\/tr>
Mechanism<\/strong><\/td>Targets EpCAM (on tumor cells) and CD3 (T\u2011cell activation)<\/td><\/tr>
Indication<\/strong><\/td>Malignant pleural effusion (MPE)<\/td><\/tr>
Approval<\/strong><\/td>FDA Phase Ib\/II clinical trial authorization<\/td><\/tr>
Study Design<\/strong><\/td>Open\u2011label, multicenter<\/td><\/tr>
Clinical Need<\/strong><\/td>MPE is a common, serious complication of advanced lung\/breast cancer; current treatments are palliative<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Strategic Outlook<\/h2>\n\n\n\n